{"id":46870,"date":"2022-08-03T11:02:23","date_gmt":"2022-08-03T09:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/"},"modified":"2022-08-03T11:02:23","modified_gmt":"2022-08-03T09:02:23","slug":"kurin-inc-statement-regarding-patent-litigation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/","title":{"rendered":"Kurin, Inc. Statement Regarding Patent Litigation"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin\u00ae<\/sup> blood culture collection sets, today released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies.\n<\/p>\n

<\/a><\/p>\n

\nMagnolia Medical originally asserted four patents in the case. By the time of the trial, all of these patents were dropped, except one having only two asserted claims. The Delaware jury concluded that Kurin infringed the single Magnolia patent, and awarded a royalty on each Kurin Lock set sold during a certain time period. The verdict will not prevent Kurin from maintaining the uninterrupted supply of its market-leading Kurin Lock to hospitals \u2013 and will allow it to continue implementing its plans.\n<\/p>\n

\n\u201cWhile we strongly disagree with some aspects of the Jury\u2019s decision, we are pleased that this chapter of the litigation has concluded and that it does not impede our ability to continue operating. The conclusion of this trial will allow us to return our focus to delivering Kurin Locks to the customers and patients who need them, and advancing this important solution to effectively address the blood culture contamination problem,\u201d said Bob Rogers, Inventor and CEO of Kurin.\n<\/p>\n

\nKurin\u2019s revolutionary and disruptive approach automatically and passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff.<\/i> infection. Contaminated blood cultures also create a financial burden to hospitals by prolonging hospital stays.\n<\/p>\n

\nAbout Kurin, Inc.<\/strong>\n<\/p>\n

\nKurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNathan Miller or Ryan McCrimmon
\n
Kurin, Inc.
\n
310-571-8264
\n
Nathan@miller-ink.com<\/a> or Ryan.McCrimmon@miller-ink.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin\u00ae blood culture collection sets, today released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies. Magnolia Medical originally asserted four patents in the case. By the time of the trial, all of these patents were dropped, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46870","6":"format-standard","7":"category-industry"},"yoast_head":"\nKurin, Inc. Statement Regarding Patent Litigation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kurin, Inc. Statement Regarding Patent Litigation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin\u00ae blood culture collection sets, today released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies. Magnolia Medical originally asserted four patents in the case. By the time of the trial, all of these patents were dropped, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-03T09:02:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kurin, Inc. Statement Regarding Patent Litigation\",\"datePublished\":\"2022-08-03T09:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/\"},\"wordCount\":342,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005080\\\/en\\\/1532339\\\/21\\\/KurinLOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/\",\"name\":\"Kurin, Inc. Statement Regarding Patent Litigation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005080\\\/en\\\/1532339\\\/21\\\/KurinLOGO.jpg\",\"datePublished\":\"2022-08-03T09:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005080\\\/en\\\/1532339\\\/21\\\/KurinLOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005080\\\/en\\\/1532339\\\/21\\\/KurinLOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-statement-regarding-patent-litigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kurin, Inc. Statement Regarding Patent Litigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kurin, Inc. Statement Regarding Patent Litigation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/","og_locale":"en_US","og_type":"article","og_title":"Kurin, Inc. Statement Regarding Patent Litigation - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin\u00ae blood culture collection sets, today released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies. Magnolia Medical originally asserted four patents in the case. By the time of the trial, all of these patents were dropped, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-03T09:02:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kurin, Inc. Statement Regarding Patent Litigation","datePublished":"2022-08-03T09:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/"},"wordCount":342,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/","url":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/","name":"Kurin, Inc. Statement Regarding Patent Litigation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg","datePublished":"2022-08-03T09:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220803005080\/en\/1532339\/21\/KurinLOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-statement-regarding-patent-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kurin, Inc. Statement Regarding Patent Litigation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46870"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46870\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}